Summary

Crossject SA (Crossject) is a medical device company that develops needle-free, pre-filled, single-use and fixed dose injection system based on chemicals and biologics. The company’s products include methotrexate, epinephrin, sumatriptan, L15, naloxone, apomorphine, and midazolam. It uses its needle-free injection system to develop a Pipeline of supergenerics by combining drug molecules with zeneo. Crossject’s zeneo is the exclusive needle-free injection system that can deliver drugs intradermally, subcutaneously and intramuscularly. The company develops supergenerics in the therapeutic area of rheumatoid arthritis, anaphylactic shock and acute migraine. It markets its products through its network of distributors. Crossject is headquartered in Chenove, France.

This Report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.

The report enhances decision making capabilities and help to create effective counter strategies to Gain Competitive Advantage.

Scope:

The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments

The report analyzes all pipeline products in development for the company Crossject SA

The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)

The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date

The report provides detailed description of products in development, technical specification and functions

The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design , trial status and phase, estimated start and end date.

Reasons To Buy:

Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape

Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio

To formulate effective Research & Development strategies

Develop market-entry and market expansion strategies

Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop competition strategies by identifying the status and likely launch of the competitors’ pipeline products through review of the clinical trials, stage and of development, etc

Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio

The post Crossject SA ALCJ-Product Pipeline Analysis, 2016 Update appeared first on Ken Research.